SUBA-itraconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary.
The FDA has approved Mayne Pharma Group Limited’s New Drug Application for SUBA-itraconazole (Tolsura) 65mg capsules.
New study data reinforce the long-term efficacy and safety of Amgen’s evolocumab (Repatha) in individuals at risk for heart attack and stroke, but an additional analysis highlights challenges associated with use of lipid-lowering therapies (LLTs) in these patients.
A patient-centric approach is vital to effective specialty pharmacy services.
Study shows that routinely screening inmates for hepatitis C virus at entry may identify a significant number of cases that would have been missed through targeted testing.
Top news of the day across the health care landscape.
Top news of the day across the health care landscape
Experts argue whether a decline in cognitive function should lead to a change in disease-modifying therapy for multiple sclerosis.
The manufacturer of the active pharmaceutical ingredient found in the medication has received a letter from the agency.
